Bharat Biotech, Serum Institute arm Bilthoven Biologicals to collaborate for oral polio vaccine 

The Hyderabad-based Bharat Biotech will procure drug substances manufactured in the Netherlands at Bilthoven Biologicals for the vaccines

April 02, 2024 03:14 pm | Updated 10:05 pm IST - HYDERABAD

Image used for representation purpose only. Fie

Image used for representation purpose only. Fie

Bharat Biotech and Bilthoven Biologicals B.V. (Bbio), the Netherlands-based subsidiary of Serum Institute of India, have signed an agreement to produce in India oral polio vaccines (OPVs) made with drug substances sourced from the Dutch firm. They will jointly obtain regulatory approvals and licences required to commercially manufacture OPVs in India for supply to domestic as well as global markets, the two companies said in a release.

Their collaboration is to strengthen the production and supply security of OPVs and support the efforts to create a polio-free world, they said, announcing signing of a requisite agreement.

“Our vision is to eradicate polio worldwide... delighted to join forces with Bharat Biotech to reinforce the global supply of polio vaccines,” Serum Institute of India CEO Adar Poonawalla said.

Bharat Biotech is one of the largest manufacturers of oral vaccines globally with an capacity to produce 500 million doses a year. Biopolio, the company’s existing OPV and a WHO pre-qualified vaccine, will remain as eradication of polio is a global initiative and important for India’s future. The company will ensure uninterrupted supply of polio vaccines, a spokesperson said.

“Oral polio vaccines have been an integral part of the government of India’s universal immunisation programme for decades, with Bharat Biotech being one of the largest suppliers to immunisation programmes across the world. The [latest] collaboration exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation’s mission to eradicate polio,” Executive Chairman Krishna Ella said in the release.

Bilthoven Biologicals was the first international acquisition of Serum Institute of India. When the bioengineering and pharmaceutical company was acquired from the Netherlands government in June 2012, it ensured access to technology and expertise for making the IPV (Injectable Polio Vaccine, Salk), earlier possessed by only three other vaccine manufacturers, for the Pune-based vaccine maker. Bilthoven Biologicals is spread over 40 acres with an installed manufacturing capacity of over 20 million doses of vaccines annually.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.